By turning a capability once reserved for specialized computational teams into a self-service product on Amazon SageMaker, SandboxAQ extends its Large Quantitative Models into a market that underpins the majority of the world’s manufactured goods 

PALO ALTO, Calif., Aug. 25, 2026 — SandboxAQ today announced that AQCat, its Large Quantitative Model (LQM) for catalyst discovery, is now generally available in AWS Marketplace and deployable through Amazon SageMaker. The release makes one of the company’s most commercially significant scientific tools available on demand to materials innovators, industrial giants, and discovery teams, who can now run it directly inside their own AWS environment, with no specialized computational scientists or custom code required.

Catalysts are the hidden engine of the physical economy. They are essential to the production of more than 80% of all manufactured goods and over 90% of all commercially produced chemicals, from fertilizer and fuel to fabric, glass, and plastics. Yet the process of discovering better catalysts has remained slow and costly, with conventional laboratory methods typically able to evaluate fewer than 100 candidates per week, a pace that confines most innovation to incremental improvements on existing materials.

AQCat removes that bottleneck. Trained on 13.5 million high-fidelity quantum chemistry calculations spanning 47,000 catalyst systems, it predicts the key properties that determine catalyst performance at up to 20,000 times the speed of conventional physics-based methods while approaching their accuracy. For chemical leaders, that means screening and ranking vast numbers of candidate materials computationally, then reserving costly laboratory and supercomputing work for only the strongest leads. This allows users to compress R&D timelines and de-risk investment across the pipeline.

Making AQCat generally available in AWS Marketplace marks a shift from bespoke scientific engagements to scalable, self-service commercial distribution. Customers can subscribe and deploy within infrastructure they already use and trust, keeping every calculation inside their own AWS account for security and governance. The launch extends a cloud go-to-market strategy that also spans Anthropic, where SandboxAQ offers users access to AQCat via MCP. 

“Highly efficient machine learning interatomic potentials such as AQCat will rapidly accelerate the evaluation of promising new materials and deepen our understanding of their complex transformations,” said Julia Yang, Assistant Professor, School of Chemical and Biomolecular Engineering, Georgia Institute of Technology.

“Catalysis touches nearly everything the global economy produces, yet the tools to discover better catalysts have barely changed in decades,” said Jack Hidary, CEO of SandboxAQ. “By making AQCat available in AWS Marketplace, we’re putting a capability that once required specialized teams and supercomputers into the hands of any enterprise research team, on infrastructure they already trust. This is how we scale our Large Quantitative Models from breakthrough science into everyday commercial impact.”

AQCat’s advantage lies in both reach and fidelity. It is built to account for spin polarization, a physical effect essential to accurately modeling widely used industrial metals such as iron, nickel, and cobalt, and it supports six additional industrially relevant elements (barium, cerium, fluorine, lithium, lanthanum, and magnesium) that are absent from other datasets. Together, these capabilities open the door to catalysts and critical-material pathways that older methods could not reach, with direct applications in green hydrogen, sustainable aviation fuel, fertilizer production, and plastics recycling.

AQCat is generally available to AWS commercial customers in North America in AWS Marketplace. To get started, subscribe at AWS Marketplace: AQCat – AI Models for Catalyst Discovery.

About SandboxAQ
SandboxAQ is a B2B company delivering solutions at the intersection of AI and quantum techniques. The company’s Large Quantitative Models (LQMs) deliver critical advances in life sciences, financial services, navigation, and other sectors. SandboxAQ is an independent, growth-backed company funded by leading investors and strategic partners including funds and accounts advised by T. Rowe Price Associates, Inc., Google, Alger, IQT, US Innovative Technology Fund, S32, Paladin Capital, BNP Paribas, Eric Schmidt, Breyer Capital, Ray Dalio, Marc Benioff, Thomas Tull, Yann LeCun, and others. For more information, visit www.sandboxaq.com.

SOURCE SandboxAQ

-Airway Therapeutics cierra una ronda de financiación de 50 millones de dólares para impulsar el desarrollo en fase avanzada de Zelpultide Alfa

• La captación de capital respalda el ensayo clínico en curso de fase 2b/3 para la prevención de la displasia broncopulmonar y las actividades analíticas y de química clínica asociadas.
• Aproximadamente el 94 % de los inversores actuales participaron en la ronda de financiación Serie E-2.
• Se prevé que el análisis intermedio que completa la fase 2b del ensayo esté disponible a finales del segundo trimestre de 2027.

ATLANTA, 25 de agosto de 2026 — Airway Therapeutics, Inc., una empresa biofarmacéutica en fase clínica avanzada que desarrolla nuevas terapias biológicas para enfermedades respiratorias, inflamatorias e infecciosas, anunció hoy el cierre de una ronda de financiación de 50 millones de dólares para respaldar el desarrollo clínico continuo en fase avanzada de zelpultide alfa, la nueva proteína D humana surfactante recombinante (rhSP-D) de la compañía.

La ronda E consta de 26 millones de dólares recaudados previamente mediante una financiación SAFE y 24 millones de dólares a través de la ronda Serie E-2 de la compañía. Los fondos se destinarán principalmente a que Airway complete la fase 2b del ensayo clínico de fase 2b/3 que evalúa zelpultide alfa para la prevención de la displasia broncopulmonar (BPD) en bebés muy prematuros, así como a las actividades de química, fabricación y control (CMC) y analíticas necesarias para el avance del programa.

La ronda Serie E-2 contó con una amplia participación de la base de inversores de Airway, con aproximadamente el 94 % de los inversores existentes participando en la ronda. Entre los participantes se encuentran el Hospital Infantil de Cincinnati y un consorcio de grandes family offices, comprometidos con el desarrollo de terapias innovadoras para enfermedades respiratorias graves.

“Estamos sumamente satisfechos con la fuerte participación y el continuo apoyo de nuestros inversores actuales, con aproximadamente el 94 % de nuestra estructura accionarial actual participando en la ronda Serie E-2, lo que refleja su confianza en Airway, nuestro equipo y el potencial de zelpultide alfa”, dijo Marc Salzberg, MD, presidente y consejero delegado de Airway Therapeutics. “Con esta ronda, estamos bien posicionados para mantener el impulso en nuestro programa clínico de fase avanzada mientras evaluamos zelpultide alfa para la prevención de la displasia broncopulmonar en bebés muy prematuros, una población con una importante necesidad médica no cubierta y sin terapias preventivas aprobadas.”

“Esta ronda de financiación consolida aún más la posición financiera de Airway mientras llevamos a cabo el ensayo clínico de fase 2b/3 en curso y nos preparamos para los próximos hitos importantes del desarrollo del programa”, declaró Alan S. Wolk, MBA, director financiero y director de operaciones de Airway Therapeutics. “Los fondos nos proporcionan el capital necesario para respaldar el estudio clínico, así como el trabajo analítico de preparación para CMC y BLA, indispensable para avanzar con zelpultide alfa a través de las últimas etapas de desarrollo de manera disciplinada y eficiente”.

El próximo hito importante del desarrollo de Airway es el análisis intermedio previsto, que marca la finalización de la fase 2b del ensayo clínico de fase 2b/3 en curso. Se esperan los resultados del análisis intermedio para finales del segundo trimestre de 2027.

Acerca de Zelpultide Alfa
Zelpultide alfa es una proteína surfactante humana recombinante D (rhSP-D) diseñada con precisión para replicar la estructura cuaternaria completa y la función biológica de la proteína nativa, incorporando una glicosilación optimizada mediante tecnología avanzada de líneas celulares. Su actividad terapéutica se basa en tres mecanismos clave: modulación de las respuestas inmunitarias para mitigar la inflamación excesiva, mejora del reconocimiento y la eliminación de patógenos, y mantenimiento de la homeostasis del surfactante para favorecer la función pulmonar. Como plataforma biológica versátil, lzelpultide alfa se está desarrollando para pacientes de todas las edades, desde la prevención de la displasia broncopulmonar (BPD) en recién nacidos muy prematuros hasta el tratamiento de afecciones respiratorias, inflamatorias e infecciosas agudas y crónicas en adultos.

La principal indicación de zelpultide alfa, la prevención de BPD, se encuentra actualmente en fase 2b/3 de ensayos clínicos, tras un estudio de fase 1b que demostró un perfil favorable de seguridad y tolerabilidad.i

Acerca de Airway Therapeutics
Airway Therapeutics es una compañía biofarmacéutica en fase clínica avanzada que desarrolla una nueva clase de terapias biológicas para redefinir la prevención y el tratamiento de enfermedades respiratorias, inflamatorias e infecciosas. Su principal candidato, zelpultide alfa, se encuentra actualmente en fase clínica avanzada para la prevención de la displasia broncopulmonar (BPD) en bebés muy prematuros, una afección para la que no existen terapias preventivas aprobadas. Como plataforma biológica, zelpultide alfa también se está desarrollando para una aplicación más amplia en diferentes grupos de edad y contextos patológicos, con el objetivo de mejorar los resultados para poblaciones de pacientes vulnerables.

Para obtener más información, visite https://www.airwaytherapeutics.com 

Contacto de la compañía: 
Libba Muzi
Airway Therapeutics  
[email protected]
513-770-9630

SINGAPUR y ÁMSTERDAM, 25 de agosto de 2026 — SWI Capital Holding Ltd (Euronext Amsterdam: SWICH, (“Grupo SWI”), el grupo de inversión cotizado, confirma hoy el cambio estratégico que ha transformado su estrategia empresarial durante el último año: más del 80 % del capital del Grupo se destina ahora a una plataforma de infraestructura digital transatlántica que supera los 4 GW, con la ambición de aumentar su participación hasta el 90 %.

• El Grupo SWI confirma la finalización de la adquisición, previamente anunciada, de una participación mayoritaria de más del 70 % en Genesis Digital Assets (GDA), que pasará a llamarse SWI Digital.
• La infraestructura digital representa ahora más del 80 % de la asignación de capital del Grupo SWI, con la intención de aumentar esta cifra a más del 90 % con el tiempo.
• El Grupo SWI desarrollará su propia plataforma de computación de alto rendimiento (HPC) y GPU como servicio. La alianza con Polarise se transforma en colaboración financiera.
• El Grupo SWI prevé un crecimiento de dos dígitos en 2026.

Bajo el liderazgo de sus cofundadores, Max-Hervé George y Jaume Sabater, el Grupo SWI se convirtió en un grupo de inversión cotizado que invierte su propio capital en oportunidades de alto crecimiento en el mercado privado, además de sus actividades consolidadas de gestión de activos. El Grupo está acelerando el crecimiento de su actividad de inversión de capital, centrándose principalmente en centros de datos e infraestructura de IA, y prevé un crecimiento de dos dígitos en su balance para 2026.

SWI DIGITAL

Con la ayuda de Morgan Stanley & Co LLC, que actúa como asesor financiero exclusivo para la adquisición, el Grupo SWI ha conseguido, mediante adquisiciones y reestructuraciones, una participación mayoritaria de más del 70 % en GDA, que pasará a llamarse SWI Digital y será la plataforma de infraestructura digital del Grupo centrada en Estados Unidos.

INFRAESTRUCTURA DIGITAL QUE IMPULSA LA CREACIÓN DE VALOR

El Grupo SWI ha centrado estratégicamente su asignación de capital en la infraestructura digital, invirtiendo de forma constante en el sector durante los últimos cinco años para construir una cartera europea y estadounidense con una capacidad de generación de energía combinada superior a 4 GW. A día de hoy, más del 80 % del capital del Grupo SWI está destinado a la infraestructura digital, con la intención de aumentar esta cifra a más del 90 % con el tiempo. Las inversiones del Grupo SWI en infraestructura digital se basan en dos plataformas:

• AiOnX: la plataforma europea de infraestructura de IA de SWI, que desarrolla una cartera de campus de centros de datos hiperescalables preparados para la IA en Irlanda, el Reino Unido, Dinamarca, España e Italia, con un emplazamiento ya asegurado por un importante inquilino hiperescalable.
• SWI Digital (GDA): el grupo de infraestructura digital de SWI centrado en EE. UU., con una reserva de terrenos conectados a la red eléctrica y con suministro de energía, lo que proporciona a SWI una posición estratégica en el mercado de inteligencia artificial y computación de alto rendimiento más grande y de mayor crecimiento del mundo.

DE LA TIERRA Y LA ENERGÍA A LA COMPUTACIÓN: HPC Y GPU COMO SERVICIO

Más allá de la propiedad de terrenos, energía y capacidad de centros de datos, SWI Group está ascendiendo en la cadena de valor hacia la computación de IA. El Grupo aprovechará su equipo altamente experimentado y su sólida posición financiera para desarrollar internamente su plataforma propia de IA en la nube, diseñada para ofrecer computación acelerada por GPU a empresas, instituciones de investigación y desarrolladores de IA.

La combinación de los sitios energizados de AiOnX y GDA con la capa HPC del Grupo le brinda a SWI una pila de infraestructura digital integrada verticalmente, lo que permite al Grupo capturar valor en cada capa de la cadena de infraestructura de IA.

TRANSACCIÓN DE POLARISE

En relación con la asociación con Polarise anunciada a principios de este año, ambas partes acordaron mutuamente no seguir adelante con la finalización de esta transacción, tal como se había propuesto inicialmente.

En lugar de adquirir una participación mayoritaria en Polarise, el Grupo SWI proporcionará financiación para acelerar la expansión estratégica de Polarise; las dos entidades permanecerán separadas y crecerán de maneras distintas.

INICIATIVAS ESTRATÉGICAS MÁS ALLÁ DE LA INFRAESTRUCTURA DIGITAL

Más allá de la infraestructura digital, el Grupo SWI continúa albergando un conjunto diversificado de inversiones con distintos factores de rentabilidad. Estos incluyen:

• Inversiones en bienes raíces industriales y logísticos europeos a través de SERT, empresa cotizada en la Bolsa de Singapur con calificación de grado de inversión.
• Inversiones en viviendas multifamiliares en EE. UU. a través de Varia US, que cotiza en la Bolsa de Valores SIX de Suiza.
• Una creciente apuesta por la cultura, el deporte y el entretenimiento, sectores en los que el Grupo SWI identifica atractivas oportunidades de inversión antes del consenso institucional.
• Una estrategia oportunista e independiente de la clase de activos, que invierte en oportunidades que el Grupo identifica en diversos mercados, incluyendo situaciones de crisis y activos financieros.

Max-Hervé George, cofundador y consejero delegado del Grupo SWI, declaró: “Nuestra transformación en un grupo de inversión cotizado nos proporcionó la solidez financiera y la agilidad necesarias para respaldar las tendencias que creemos que definirán la próxima década. La infraestructura digital es fundamental para esta convicción, y la creación de SWI Digital representa un paso decisivo para el Grupo”.

Jaume Sabater, cofundador del Grupo SWI y consejero delegado de Stoneweg, añadió: “La cotización en Euronext Amsterdam nos ha permitido centrarnos en invertir nuestro propio balance con disciplina y convicción. Esto posiciona al Grupo para generar valor con rapidez y a gran escala. La adquisición de nuestra participación mayoritaria en GDA es la prueba más clara de esta estrategia hasta la fecha”.

Esta nota de prensa contiene información privilegiada en el sentido contemplado por el Reglamento (UE) 596/2014 sobre Abuso de Mercado.

Acerca del Grupo SWI

El grupo SWI (SWI Capital Holding Ltd) es un grupo de inversión global especializado en mercados privados, que cotiza en Euronext Amsterdam con el símbolo SWICH. Fruto de la fusión de Icona y Stoneweg, el Grupo invierte su propio capital en infraestructura digital, bienes raíces y otras oportunidades en el mercado privado, combinando un enfoque emprendedor con la disciplina institucional. Para más información, visite www.swi.com.

Web: www.swi.com 

Declaraciones prospectivas

Este comunicado de prensa contiene declaraciones prospectivas, incluidas declaraciones sobre la estrategia del Grupo SWI, la asignación de cartera y el cambio de marca previsto de GDA a SWI Digital. Dichas declaraciones se basan en las expectativas y suposiciones actuales y están sujetas a riesgos, incertidumbres y otros factores conocidos y desconocidos que pueden causar que los resultados, el desempeño o los eventos reales difieran sustancialmente de los expresados o implícitos. En particular, no se puede garantizar que ninguna transacción, reestructuración o cotización a la que se hace referencia en este documento se complete en los términos descritos, ni que se complete en absoluto, ni dentro del plazo indicado. El grupo SWI  no asume ninguna obligación de actualizar o revisar ninguna declaración prospectiva, ya sea como resultado de nueva información, eventos futuros o de otro modo, salvo que lo exija la ley. Este comunicado tiene fines meramente informativos y no constituye ni forma parte de una oferta o solicitud para comprar, suscribir o vender valores.

Companies from across the country will pitch live to government and investor judges in Montgomery County, Maryland, September 9–10. Registration is free for government employees.

SILVER SPRING, Md., Aug. 25, 2026 — CivStart today announced the eleven startups selected to pitch at State of GovTech 2026, the organization’s seventh annual national govtech summit, taking place September 9–10 at the Silver Spring Civic Building in Montgomery County, Maryland.

The selected companies span permitting, public safety, emergency management, grant administration, constituent services, and civic infrastructure finance. They will pitch live on the main stage to a judging panel drawn from local government, county technology leadership, and the govtech investment community.

The 2026 Startup Cohort

• Appellate  (Bentonville, AR) — system of record for police towing and vehicle custody
• Ayla  (Washington, D.C.) — public-sector recruiting on a live government labor-market data engine
• CODICE  (Washington, D.C.) — no-code permitting, licensing, and inspections platform
• Gostly  (Westminster, MD) — real-time command center for urban infrastructure
• Grantwell  (Los Angeles, CA) — AI grant management across the full lifecycle
• Green Stream Technologies (Wake Forest, NC) — flood and weather early warning systems
• Govstream  (Seattle, WA) — AI-driven permitting intake
• Labrynth  (US, Australia, EU, UK) — AI-native regulatory intelligence for permitting
• ManyBond — crowdfinancing for community-supported local investment
• Readyly  (Connecticut) — agentic AI resolving resident inquiries across every channel
• Samora AI  (Bellevue, WA) — multilingual voice AI for citizen information lines

The Judging Panel

• Hillary Orr, Deputy Director of Transportation, City of Alexandria, Virginia 
• Rita Reynolds, Director of Public Sector, CAI 
• Thao Hill, Co-Founder and CEO, Govinity 
• Tom Spenger, CEO, SOVRA 
• Eyal Feder-Levy, CEO, Zencity

The pitch competition is one part of a two-day agenda built around working sessions rather than passive programming. Attendees draft AI use policies, run live cybersecurity breach simulations, and bring unresolved problems from their own jurisdictions to work through with peers.

State of GovTech 2026 is expected to draw more than 200 attendees, split roughly evenly between public sector leaders and the entrepreneurs, investors, and industry practitioners who serve them. The venue sits directly on the Washington Metro, and registration is free for government employees. Full agenda and registration at civstart.com/sogt26.

About CivStart

CivStart is a govtech organization connecting government leaders with the technology solutions and entrepreneurs solving public sector challenges. Through its accelerator programs, industry events, and products including Clarity and GovFit, CivStart helps state and local governments define their challenges and find partners equipped to solve them. State of GovTech is CivStart’s flagship annual summit, now in its seventh year. Learn more at civstart.com.

Media Contact:

Nick Lyell

Co-Founder & COO

[email protected] | 608.234.2166

SOURCE CivStart

Seasoned enterprise security leader brings decades of experience building and scaling category-defining cybersecurity businesses

SALT LAKE CITY and LONDON, Aug. 25, 2026 — Netcraft, the global leader in brand protection and threat disruption, today announced that cybersecurity industry veteran Darren Lee has joined its board of directors. The appointment comes as Netcraft accelerates its growth, as a leader in Next-Generation Brand and Digital Risk Protection, taking down nearly one-third of the world’s phishing sites. Lee brings decades of experience building, scaling, and expanding enterprise technology and cybersecurity businesses, including more than 14 years scaling Proofpoint, where he helped transform the company into one of the world’s preeminent cybersecurity brands.

Netcraft is trusted by CISOs and security teams at many of the world’s most valuable companies, largest banks, and government organizations to detect and disrupt external threats at scale. Processing more threat data than any other provider, the company has blocked more than 230 million multichannel threats to date. As attackers increasingly use AI to accelerate phishing, brand impersonation, and fraud, Netcraft has expanded beyond industry-leading takedowns into preemptive disruption, dismantling criminal infrastructure before it can be weaponized. Lee’s addition brings deep product and go-to-market experience as the company continues to accelerate its global expansion.

Lee joined Proofpoint following acquisition of NextPage, an information governance company where he served as CEO. At the time of the acquisition, Proofpoint was a private company generating less than $100 million in annual recurring revenue (ARR). During Lee’s tenure, Proofpoint went public via U.S. IPO, scaling to more than $2 billion in ARR and more than 4,000 employees around the world. Lee played a significant role in that growth, holding a series of senior leadership positions spanning some of Proofpoint’s most important businesses and strategic initiatives.

In joining the board of directors, Lee will bring his experience scaling cybersecurity products, portfolios, and go-to-market strategies to Netcraft as the company continues to accelerate its growth as a leader in Next-Generation Brand and Digital Risk Protection and expand its suite of solutions.

Darren Lee, board member, Netcraft, said: “Netcraft has built something uniquely difficult to replicate: decades of actionable, proprietary threat intelligence combined with direct connections and longstanding relationships with internet infrastructure providers, and the ability to effectively disrupt criminal infrastructure. The opportunity for security leaders now is to build on that foundation, leveraging innovative tools and capabilities to identify more proactive ways to protect their brands and customers. I look forward to working with the Netcraft team as they continue to strengthen their market-leading position and expand their solutions that help security leaders take decisive action to stop cybercrime.”

Ryan Woodley, CEO, Netcraft, said: “Darren has a rare perspective in cybersecurity, as he has built companies as an entrepreneur and then helped scale one of the industry’s most successful security businesses through multiple stages of growth. He understands what it takes to expand a product portfolio, build enduring customer value, and establish a cybersecurity company as a category leader. That experience will be incredibly valuable as Netcraft enters its next phase of growth.”

About Netcraft
Netcraft is a global leader in online brand protection and digital risk management, trusted by CISOs and security teams at many of the world’s most valuable companies, largest banks, government organizations, and emerging enterprises. Leveraging AI, machine learning, and automation to process more threat data than any other provider, Netcraft takes down nearly one-third of the world’s phishing sites and has blocked 230+ million multi-channel threats to date. Backed by a deep network across the internet infrastructure ecosystem, Netcraft delivers unmatched visibility, speed, and accuracy at scale to disrupt criminal behavior and secure online trust for consumers around the globe. Learn more at www.netcraft.com.

Media Contact:
Corey Eldridge
Force4 Technology Communications, LLC
[email protected]

SOURCE Netcraft

ATLANTA, Aug. 25, 2026 — Noble Investment Group (“Noble”) today announced that Matt Noland has joined the firm as Director, Capital Markets, where he will focus on strategic asset realizations and debt origination and management across Noble’s portfolio.

Prior to joining Noble, Mr. Noland was with Peachtree Group, where he was responsible for portfolio management and the execution of hospitality investment transactions, including the acquisition and disposition of hotel assets.

Earlier in his career, Mr. Noland was a member of the Debt Capital Markets team at JLL, where he supported the placement of nearly $1.0 billion of debt and equity capital for acquisitions, refinancings, and ground-up developments. He also held roles in credit and investment banking at Truist Securities and SunTrust Robinson Humphrey. Mr. Noland earned a B.S. from Clemson University and is currently completing his M.B.A. at Emory University’s Goizueta Business School.

“Matt has raised debt, managed assets, and executed dispositions – the full arc of a hold period,” said Adi Bhoopathy, Managing Principal and Head of Capital Markets at Noble. “That combination strengthens how we structure capital at entry, manage risk through the cycle, and realize value at exit.”

“Noble has built one of the most respected platforms in the sector, with real operating capability behind every asset,” said Mr. Noland. “I look forward to helping shape capital strategy for a portfolio of this scale, alongside a team that has invested through multiple cycles.”

About Noble
Founded in 1993, Noble is an alternative asset manager focused exclusively on the travel and hospitality sector. With more than $5 billion in assets under management and over three decades of experience investing through market cycles, Noble invests on behalf of leading institutional investors, including public pension plans, endowments, foundations, insurance companies, and wealth managers.

The firm’s vertically integrated platform brings together investment, asset management, design and development, and operating capabilities to identify opportunities, manage risk, and drive performance across the upscale select-service, upscale extended-stay, and branded long-term accommodations segments. Noble’s scale, sector specialization, proprietary data, and operating experience inform investment decisions across the platform and underpin the firm’s ability to identify inflection points early and act on them. Noble is recognized among PERE’s Top 200 Global Investment Managers.

Learn more at www.nobleinvestment.com.

SOURCE Noble Investment Group

Continued Investor Demand Led by Insurers Underscores Growing Appeal
for Scaled Exposure to the C-PACE Asset Class

NEW YORK, Aug. 25, 2026 — Nuveen, one of the largest asset managers globally with over $1.4 trillion AUM¹, and Nuveen Green Capital (“NGC”), a Nuveen affiliate and a leading provider of sustainable commercial real estate financing solutions with over $6 billion in AUM, today announced a first close exceeding $1 billion in new capital commitments for Nuveen CPACE Lending Fund IV. This brings total commitments to the Fund Series to $3 Billion since the series’ inception in 2023.

Founded in 2015, Nuveen Green Capital is a pioneer in Commercial Property Assessed Clean Energy (C-PACE) financing. C-PACE is a public-private financing program administered at the state level that provides building owners and developers with low-cost, long-term private capital for these upgrades.

Nuveen CPACE Lending Fund IV builds on the momentum of Nuveen Green Capital’s 73% year-over-year growth, driven by proprietary originations volume from vertically integrated originations and investment management. Consistent with prior vintages, Fund IV provides investors with predictable deployment into attractive investment-grade assets that offer the potential for long-dated, steady returns while financing capital improvements that make commercial buildings more energy efficient, water efficient, and climate resilient.

“Investors have committed to this strategy across four vintages because the fundamentals remain steady throughout variable market cycles. NGC’s vertically integrated platform continues to deliver a scaled, proprietary flow of C-PACE assets originated with established sponsors, combining compelling economics with measurable impact,” said Alexandra Cooley, CEO and CIO of Nuveen Green Capital. “The momentum behind this raise has been bolstered by our track record of strong origination volume, deployment, and consistent performance. Since 2015, NGC has originated more than $6 billion in C-PACE financings across securitizations. Fund IV strengthens our leadership position with increasing balance sheet capacity that institutional borrowers value.”

Nuveen’s 2026 EQuilibrium survey of global institutional investors shows that North American insurers continue to prioritize private fixed income, with 46% planning to increase their private fixed income allocations over the next two years — and among those, 53% identify private asset-backed securities like C-PACE as a key target asset class.²

“The continued growth in commitments from across four funds tells us that insurers aren’t just testing this asset class – they’re building meaningful, repeatable allocations to it,” said Joseph Pursley, Nuveen Head of Insurance, Americas. “Life insurers in particular continue to prioritize longer duration, investment grade, asset-backed securities with attractive risk-adjusted returns, and NGC’s C-PACE strategy consistently delivers on that mandate while advancing climate resiliency at scale. The demand we’re seeing for Fund IV – including new insurance LPs – reinforces that this is becoming a durable, core allocation for insurance portfolios rather than a one-off commitment.”

Growth of the asset class is supported by continued expansion of the C-PACE program, which is now active in 39 states plus the District of Columbia. As more states adopt C-PACE legislation and refine their programs, NGC’s addressable market continues to widen, further supporting the origination pipeline behind Fund IV. This is reflected in the diversity of transactions closed across the platform in 2025 – from $5 million transactions to those exceeding hundreds of millions, such as The Geneva, a landmark office-to-residential conversion in Washington, D.C., the largest C-PACE financing in history.³

Media Contact

Andrew Chironna, [email protected], 212-913-1015

About Nuveen

Nuveen is a global investment leader, managing $1.4T in public and private assets for clients around the world, as of June 30, 2026. With broad expertise across income and alternatives, we invest in the growth of businesses, real estate, infrastructure, and natural capital, providing clients with the reliability, access, and foresight unique to our 125+ year heritage. Our prevailing perspective on the future drives our ambition to innovate and adapt our business to the changing needs of investors — all to pursue lasting performance for our clients, our communities, and our global economy. For more information, please visit www.nuveen.com.

This vehicle is only available to accredited investors

Important information on risk

Past performance is no guarantee of future results. All investments carry a certain degree of risk, including the possible loss of principal, and there is no assurance that an investment will provide positive performance over any period of time. Certain products and services may not be available to all entities or persons. There is no guarantee that investment objectives will be achieved.

Investors should be aware that alternative investments are speculative, subject to substantial risks including the risks associated with limited liquidity, the potential use of leverage, potential short sales and concentrated investments and may involve complex tax structures and investment strategies. Alternative investments may be illiquid, there may be no liquid secondary market or ready purchasers for such securities, they may not be required to provide periodic pricing or valuation information to investors, there may be delays in distributing tax information to investors, they are not subject to the same regulatory requirements as other types of pooled investment vehicles, and they may be subject to high fees and expenses, which will reduce profits.

C-PACE assets are subject to various risks, including but not limited to: risks of insufficient cash flow of the subject property due to impaired operations or value; risks of a decline in the real estate market or financial conditions of a major tenant; risks of delinquencies and defaults; failure of the subject properties to complete agreed upon construction, repairs or improvements or achieve projected energy savings; limited operating history of certain subject properties; risk of assessments underlying certain C-PACE assets failing to comply with applicable state or local laws; risks of disputes with subject property owners and mortgage lenders; environmental contamination risks affecting the subject property; lack of industry-wide prepayment information available for commercial C-PACE assessments; and changes in laws and policies impacting C-PACE programs.

Responsible investing incorporates Environmental Social Governance (ESG) factors that may affect exposure to issuers, sectors, industries, limiting the type and number of investment opportunities available, which could result in excluding investments that perform well.

Nuveen considers ESG integration to be the consideration of financially material environmental, social and governance (ESG) factors within the investment decision making process. Financial materiality and applicability of ESG factors varies by asset class and investment strategy. ESG factors may be among many factors considered in evaluating an investment decision, and unless otherwise stated in the relevant offering memorandum or prospectus, do not alter the investment guidelines, strategy or objectives. Select investment strategies do not integrate such ESG factors in the investment decision making process.

The data and claims included in the material have not been verified by an independent third party.

Nuveen Green Capital is an indirect subsidiary of Nuveen LLC and Teachers Insurance and Annuity Association of America (TIAA) and a member of the TIAA group of companies.

¹ As of June 30, 2026
² Nuveen 2026 Global Institutional Investor Survey, EQuilibrium Insurance Edition.
³ Commercial Observer, Nuveen Green Capital Originates Record C-PACE Financing With $465M D.C. Deal (January 6, 2026)

SOURCE Nuveen

BEIJING, Aug. 25, 2026 — On August 25, Haisco Pharmaceutical Group Co., Ltd. (“Haisco”) (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Sentivera, a new US venture founded by Population Health Partners (“PHP”) and ARCH Venture Partners (“ARCH”), to grant Sentivera the rights to develop, manufacture, and commercialize its independently developed one pre-clinical innovative drug globally, excluding Greater China.

The total deal value reaches over USD 1.5 billion, including an upfront payment and equity consideration in the new venture totaling USD 75.89 million, up to USD 1.46 billion in development, regulatory, and commercial milestone payments, and mid-single digits to low double digit tiered royalties on post‑launch net sales.

As a core immunology asset of Haisco, this asset inhibits the development and progression of type 2 inflammatory diseases. This asset received China IND approval this month. Preclinical studies have demonstrated that this asset exhibits strong anti-inflammatory activity with a favorable safety profile.

This collaboration brings together multiple internationally renowned life sciences investors, underscoring strong market confidence in the project, representing a significant milestone in the internationalization of innovative drugs originating from China, and an opportunity to improve healthspan globally with a scalable potential solution for a broad range of inflammatory conditions.

Haisco stated that this collaboration is highly aligned with its international strategy and is expected to generate sustainable cash flow and long‑term investment returns. Unlike the traditional “license‑out” collaboration model, this transaction adopts a Newco partnership structure. This enables deeper strategic alignment and shared growth with Sentivera and its investors, marking an upgrade in Haisco’s global expansion strategy. Haisco remains highly confident in the future global market performance of this asset.

Haisco will continue to focus on areas of unmet clinical needs, strengthen independent innovation and global collaboration, and strive to bring China‑developed original medicines to patients around the world.

About Population Health Partners

Population Health Partners, L.P. (“PHP”) is a life sciences investment and company-building firm focused on solving the health and economic challenges posed by prevalent diseases and extending human healthspan. PHP combines disciplined capital with deep scientific, clinical-development and operating expertise to identify high-impact therapeutic opportunities, form and build companies around them, and advance medicines efficiently through development—with the goal of delivering population-scale health impact and attractive risk-adjusted returns.

About ARCH Venture Partners

ARCH Venture Partners is a founder and early-stage investor in groundbreaking biotech and technology platform companies. The firm is a recognized leader in creating world-leading organizations, while combining science-driven innovation with exceptional management teams. For four decades, ARCH has pioneered disruptive innovation while building life changing solutions that revolutionize healthcare and frontier technology. 

About Haisco

As a benchmark enterprise in China’s innovative drug sector, Haisco builds on a core strategy of “innovation‑driven growth and global expansion”. Haisco has established a diversified R&D pipeline encompassing small‑molecule innovative drugs, biologics, and high‑end generics. Haisco is actively advancing more than 70 R&D programs across key therapeutic areas including immunology, respiratory, oncology, metabolic disorders, central nervous system diseases and pain management; notably, over 10 of these programs are now in pivotal clinical stages. The company has maintained a sustained commitment to R&D, with investment averaging more than 15% of revenue in each of the last three years. It has established three major R&D centers in Chengdu, Shanghai and Silicon Valley, and built a research team led by top experts from China and abroad, forming a dual‑engine innovation system combining in‑house R&D and external collaboration.

As early as 2015, Haisco initiated its global strategy and has since actively expanded into overseas markets through multiple models, including license‑out transactions, co‑development partnerships, and overseas mergers and acquisitions. The company has previously out‑licensed several innovative drugs to international partners across Europe, the United States, and Southeast Asia. The collaboration with Sentivera deepens global engagement by integrating international capital and clinical resources, accelerating the translation of innovation programs worldwide and laying a solid foundation for more original drugs to enter global markets.

SOURCE Haisco Pharmaceutical Group

Los Altos, California-based firm recognized in TIME and Statista’s 2026 ranking, following its inclusion in the award’s inaugural 2025 list

LOS ALTOS, Calif., Aug. 25, 2026 — Foothill Ventures, a Los Altos, California-based venture capital firm focused on early-stage technology investments, today announced it has been named to TIME‘s America’s Top Venture Capital Firms list for 2026. This marks the second consecutive year Foothill Ventures has earned the distinction, following its inclusion in the list’s inaugural 2025 edition.

The annual ranking, produced by TIME in partnership with Statista, evaluates the nation’s leading venture capital firms using a weighted methodology that accounts for fundraising, investment activity, performance, and leadership.

Founded in 2017, Foothill Ventures backs technical founders building breakthrough companies, working alongside them from seed stage onward. Its current investment focus spans agentic AI, physical AI, and compute infrastructure, with more than 160 portfolio companies across three funds to date.

“This recognition reflects the extraordinary founders we’re lucky to back, the conviction our limited partners bring to every fund, and the relentless work our team puts in behind every deal,” said Jinlin Wang, Managing Partner of Foothill Ventures. “We’re grateful to TIME and Statista, and even more energized to keep backing the founders building the next generation of technology companies.”

About Foothill Ventures

Foothill Ventures is a Los Altos, California-based venture capital firm founded in 2017 that invests in early-stage, technical founders. For more information, visit https://www.foothill.ventures.

SOURCE Foothill Ventures